MedTrace Logo

Comparison Between Rectal & Sublingual Misoprostol Before Caesarian Section To Reduce Intra & Post-Operative Blood Loss

NCT02083107 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 636

Last updated 2015-12-22

Study results available
· View outcomes & findings →

Summary

The aim of the work is to evaluate \& compare the effectiveness of rectally administered PGE1 synthetic analogue (misoprostol) 400 microgram versus sublingually administered misoprostol before caesarean section to decrease blood loss during and after the operation.

Conditions

  • Postpartum Hemorrhage

Interventions

DRUG

Misoprostol

Comparison of different routes of administration of 400 micro gram misoprostol

OTHER

Placebo

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Mohamed S. Sweed, MD · Ain Shams University

  • Mourad M. El-Said, Professor · AinShams University

  • Amgad E. Abou-Gamrah, Ass.Prof. · AinShams university

  • Haitham El-Sabe, MD · AinShams University

  • Mohamed M. AbdEl-Hamid, Registrar · AinShams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02083107 on ClinicalTrials.gov